Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool July 13, 2004 Brian Gorman	The "Cialis Promise" Eli Lilly and Icos are offering a free trial of their drug Cialis for men who have never used it before and promise that participants not pleased with the results will receive a voucher for a competing product.
BusinessWeek October 27, 2003 Michael Arndt	Is Viagra Vulnerable? Eli Lilly's Cialis lasts for 36 hours -- and a $100 million ad blitz will spread the word.
The Motley Fool November 21, 2008 Brian Orelli	Viagra Stays Behind the Counter All puns about soft sales and wishing something would go up in this market have been removed from this article.
The Motley Fool May 27, 2005 Nick Baker	Mama Always Said You'd Go Blind Urban legends aside, what do new concerns about Viagra and Cialis mean for investors?
The Motley Fool October 22, 2007 Brian Orelli	New Warnings Won't Sink ED Drug Sales Shockingly, new safety warnings won't hurt erectile dysfunction drugs. Any investor jumpiness should be looked at as a buying opportunity for smart investors.
The Motley Fool October 17, 2006 Brian Lawler	Lilly Doesn't Like Sharing Profits The company is buying out ICOS Corporation, its partner in erectile-dysfunction drug Cialis. Investors, take note.
The Motley Fool January 10, 2008 Brian Orelli	Good News for Lucky Men Eli Lilly's erectile dysfunction drug can now be taken daily.
The Motley Fool January 22, 2007 Brian Lawler	Adios, ICOS The pharmaceutical gets finally consumed by Eli Lilly. The deal offered a nice premium to ICOS shareholders. At the same time, it was a good deal for Lilly.
The Motley Fool April 20, 2004 Alyce Lomax	Pfizer's Fight First-quarter earnings give mixed messages on the drug maker's meds.
The Motley Fool August 16, 2011 Brian Orelli	Keeping Those Little Blue Pill Sales Up Pfizer wins a patent lawsuit for Viagra.
The Motley Fool November 24, 2010 Brian Orelli	A Manly FDA Approval Eli Lilly has something to be thankful for this week; the Food and Drug Administration approved Axiron, its testosterone replacement therapy.
The Motley Fool May 25, 2011 Brian Orelli	Satisfying Clinical Trial Straightens Up Shares VIVUS' erectile dysfunction drug avanafil works.
BusinessWeek August 15, 2005 Barrett & Weintraub	Drugmakers Are Changing Channels All those "Ask your doctor if it's right for you" ads on TV haven't delivered. As drugmakers labor to develop more educational and balanced pitches, they're also trying to better target their messages.
The Motley Fool December 11, 2008 Brian Orelli	Drugmakers Could Lose Their Greatest Weapon Congress is thinking about putting limits on direct-to-consumer advertisements. The pharmaceutical industry trade group makes a preemptive strike.
The Motley Fool May 18, 2009 Brian Orelli	Free Drugs! Pfizer's giving over 70 drugs away -- to people who have lost their jobs and health insurance recently and can show financial hardship.
Chemistry World May 7, 2013 Phillip Broadwith	Buy Viagra online - direct from the manufacturer Pharmaceutical giant Pfizer is cutting out the pharmacist middle-man by setting up a website for Viagra (sildenafil citrate) sales.
BusinessWeek March 7, 2005 Amy Barrett	Will Drugmakers Back Off The Hard Sell? Drug ads need to return to more balanced communication of risks and benefits and not depend so much on catchy phrases and images. The question is whether the industry is ready to take that lesson to heart.
The Motley Fool February 14, 2011 Brian Orelli	This Biotech Is Heating Up Biosante Pharmaceuticals was up more than 9% at one point today after the company said the independent Data Monitoring Committee believed Biosante's female sexual dysfunction drug, LibiGel, was safe enough to allow the trial to continue.
The Motley Fool December 10, 2010 Brian Orelli	Was This Drug Destined for Failure? Pfizer announces that it's pulling Thelin off the market, and withdrawing the marketing application with the Food and Drug Administration, because a new side effect was discovered.
Pharmaceutical Executive September 1, 2006 Jeannette Park	Directo to Consumer: No-Name Opportunity Marketers are using unbranded ads to get across the right messages.
BusinessWeek November 4, 2009 Arlene Weintraub	Ask Your Doctor If This Ad Is Right for You The drug industry is spending billions on TV ads, but they may be scaring consumers away
AskMen.com February 19, 2015 Christopher Asandra	The Rate Of Erectile Dysfunction Recently, the Military Times reported that the United States Department of Defense had spent nearly $300 million on drugs to treat erectile dysfunction since 2011.
The Motley Fool January 27, 2011 Rich Smith	What's Behind the Run-Up at Rexahn? The pharmaceutical's hot streak could soon burn up all its cash.
The Motley Fool January 5, 2004 Alyce Lomax	Side Effects at Lilly? Growing profits, with earnings pains.
The Motley Fool November 18, 2009 Brian Orelli	VIVUS Gets a Spark A new erectile-dysfunction drug shows promise.
The Motley Fool May 14, 2008 Brian Lawler	Teaching Old Drugs New Tricks Pfizer's top drugs post mixed results in recent off-label studies.
The Motley Fool February 29, 2008 Brian Orelli	2007 Pharma Roundup How did big pharma do in 2007? With the drug sector earnings season winding down, now seems like a good time to take a look at how they fared and, more importantly, where they're headed.
The Motley Fool September 18, 2008 Brian Orelli	Medical Device Makers Throwing Money Down the Tube Congress is investigating medical device makers' direct-to-consumer ads.
The Motley Fool August 18, 2010 Brian Orelli	No Pain Here as Jazz Shares Rocket Investors are all jazzed up about Jazz Pharmaceuticals
The Motley Fool April 16, 2009 Brian Orelli	2 Virus Killers Are Better Than 1 Glaxo brings Pfizer under its HIV wing.
AskMen.com October 30, 2015 Asandra & Palubicki	Are Erectile Dysfunction Supplements Dangerous? Here's why erectile dysfunction supplements can be extremely dangerous.
The Motley Fool May 26, 2009 Brian Orelli	Will the FDA Approve These Drugs? Plenty of Prescription Drug User Fee Act dates are right around the corner. Read on to see which pharma companies may be affected.
Chemistry World February 14, 2007 Victoria Gill	Prescription-free Viagra From today, men in the UK will be able to buy Viagra from their pharmacist without a doctor's prescription. But the trial run of the scheme has fanned the flames of a controversy about how US drug company Pfizer markets the impotence drug.
Bio-IT World February 11, 2005 Malorye A. Branca	Catching a Big Pharma Partner Deal flow: biotechs learn to squeeze value out of hot product deals when choosing a suitor.
The Motley Fool November 9, 2010 Brian Orelli	Forget R&D; Buy Your Way Into Diagnostics Eli Lilly is expanding its diagnostics business by picking up privately held Avid Radiopharmaceuticals.
BusinessWeek July 2, 2007 Arlene Weintraub	Lifestyle Drug Binge The huge profits in weight-loss and other treatments makes them hard for drugmakers to resist. But safety risks abound.
The Motley Fool May 21, 2010 Brian Orelli	And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too.
The Motley Fool February 17, 2005 Karl Thiel	Sleeping on Neurocrine's Shares Why haven't Neurocrine Biosciences shares moved? It's partly history, with delays in getting an insomnia drug to market.
Pharmaceutical Executive April 1, 2006 Diane West	Media Spend Trends: Change the Channel Drug marketers still spend lots of money. But they aim at PhRMA loopholes.
The Motley Fool October 20, 2006 Brian Lawler	Lilly Pads Its Earnings Lilly reports third-quarter 2006 numbers and gobbles up Cialis. Investors, take note.
BusinessWeek January 12, 2004	Pharmaceuticals: For Drugmakers, There's No Panacea Blockbusters are in store, but the cost of R&D, ads, and factory fixes will eat profits. Pressure from insurers and government on prices will be a drag on revenues.
The Motley Fool September 30, 2010 Brian Orelli	Avoid This Multibillion-Dollar Market It's just too crowded, but there's no doubt that psychiatric drugs are big business for some drugmakers.
BusinessWeek February 9, 2004 John Carey	Drug Ads Need Stronger Medicine New FDA guidelines may not go far enough in making sure pharmaceutical ads are used appropriately.
The Motley Fool October 28, 2004 Bill Mann	Glaxo's Mild Depression The British drug maker sees increased generic competition for its anti-depressant drugs. Total constant currency sales slipped to $7.7 billion in the current quarter from $8.5 billion last year.
AskMen.com June 23, 2004 Joshua Levine	Erection Drugs: Part II Thanks to modern medicine, a man can soon choose from a variety of new erection drugs.
BusinessWeek July 8, 2010 Simeon Bennett	Pfizer: Civil Suits for Drug Counterfeiters Pfizer's new tactics against fake drug peddlers have allowed it to recoup more than $5 million. That's still a fraction of its lost sales.
The Motley Fool December 15, 2010 Brian Orelli	Beautiful Efficacy, Wrong Pill Lexicon Pharmaceuticals presented beautiful data showing a pill it gave rheumatoid arthritis patients decreased symptoms in 49% of patients. Unfortunately, the pill was a dummy pill with no active ingredient.
The Motley Fool November 30, 2010 Brian Orelli	A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist.
The Motley Fool April 22, 2011 Sean Williams	Pharma's Most Perilous Pipelines Patent expirations expose weaknesses for these Wall Street darlings.
Chemistry World June 27, 2013 Phillip Broadwith	Ups and downs for erectile dysfunction drugs Spedra (avanafil) aims to compete for a share of the lucrative ED market, trading on the fact that it is much faster-acting than other available drugs.